FinCanna Capital Corp. (“FinCanna”) (CSE:CALI), (OTCQB:FNNZF) a royalty company for the U.S. licensed cannabis industry, announces that its portfolio company ezGreen Compliance (“ezGreen”) has completed its integration with Marijuana Tracking Enforcement Compliance (“Metrc”) for the states of California, Colorado, Maryland, Massachusetts, Montana and Oregon. ezGreen provides state-of-the-art enterprise compliance and Point-of-Sale (POS) software solutions for licensed cannabis dispensaries in the United States.

Compliance with Metrc is mandatory for all California cannabis permanent licensees. Licensees, to remain compliant must migrate their current product inventory on to the Metrc platform enabling the tracking and reporting of cannabis and cannabis products as they move through the commercial cannabis supply chain. ezGreen’s POS software supports and simplifies the maintenance of accurate reporting, inventory control and taxation requirements for licensees seeking to remain compliant.


With this integration, ezGreen becomes the first Point-of-Sale solution designed by medical, data and security professionals to be sanctioned by Cannabis Control Commissions in 6 States, with applications for certification made for the remaining Metrc States. This integration with Metrc allows ezGreen customers to substantially reduce their time and costs associated with managing product information and client data, in a fully compliant state-by-state environment.

Specifically developed to address the needs of the licensed cannabis Industry, ezGreen Compliance is a Health Insurance Portability and Accountability Act (HIPAA) certified POS solution developed and supported by Automated HealthCare Solutions (AHCS). AHCS is a leading point-of-care tracking and dispensing software solution developed over the past 17 years which currently supports 3,500+ active physician operated clinics and dispensaries, all while maintaining HIPAA compliance following essential Health and Human Services standards in the United States.

Metrc is a turnkey regulatory compliance system that provides, tracking and tracing specifically designed for government agencies regulating legalized marijuana. Metrc covers a substantial portion of the legal U.S. cannabis market having won exclusive seed-to-sale tracking contracts with twelve states, which include over 5,700 retail dispensary licenses available in their geographic coverage. Cannabiz Media.

“Cannabis industry data standards are increasingly mirroring the pharmaceutical industry’s patient data security protocols,” said Mike Coner, President of ezGreen. “Our POS solution delivers data security and integrates with any technology platform which supports operators in streamlining their operations and lowering costs related to double data entry. ezGreen also provides fully customized reporting and real time data analytics enabling businesses to make more effective decisions. With our recent integration with Metrc we are now able to deliver a complete compliance and data management solution.”

“We see this integration as the missing link that combines the Seed-to-Sale power of Metrc with the equally powerful Sale-to-State tracking and reporting delivered by ezGreen,” said Andriyko Herchak, CEO of FinCanna Capital. “Compliant operations and reporting is a “must have” for retailers and dispensaries, and this integration with Metrc positions ezGreen as a leader in the space. We anticipate strong performance from ezGreen going forward as they continue to strategically expand their market opportunity.”

Integrated via Application Programming Interface (API) with Metrc, ezGreen is now positioned to provide its POS solution to cannabis operators throughout the 6 states as a complete and comprehensive compliance and business information solution. This combined solution links the strengths of the Metrc technology which provides aggregate data regarding cultivation, production, transportation and sales of cannabis within the regulated model with ezGreen’s strengths as a POS solution that integrates with Metrc under state specific technology guidelines to protect patient and customer records while offering dispensaries custom data and analytics.

ezGreen tracks products in real time and is able to instantly identify product related discrepancies at point-of-sale, simplifying management’s ability to immediately identify and resolve any Store-to-State inventory reporting issues. ezGreen’s Point-of-Sale software also eliminates the need for manual data entry when reporting information to Metrc. As retailers or dispensaries accept inbound product information on their Metrc portal, the ezGreen information system is activated, automatically batching and labeling every product prior to sale. This seamless data exchange delivers complete compliance ensuring that products sold are reported referencing their corresponding product label tracking information versus other standard inventory tracking methods. For state’s tracking workflows that do not allow integration ezGreen provides its users the ability to generate or request custom reports, which eliminates further manual entry in Metrc or any other state tracking system.

About Metrc
First deployed in 2013 Metrc is a web-based solution made up of a browser interface and a mobile application for both the industry and regulatory users that provides end to end tracking and tracing of marijuana plants and products.  The backend is a series of secure Web Services, Database and an Application Programming Interface (API). This solution was specifically designed for government agencies in charge of legalized marijuana enforcement. Metrc provides the necessary visibility for adherence to rules, regulations and statues. Currently Metrc is contracted by the following states, Alaska, California, Colorado, Oregon, Maryland, Michigan, Ohio, Massachusetts, Montana, Nevada, Louisiana and Washington D.C.

For additional information visit https://www.metrc.com .

About ezGreen Compliance
ezGreen Compliance, located in Fort Lauderdale FL, provides through its ezGreen software technology, a proven state-of-the-art enterprise compliance and Point-of-Sale software solution for licensed medical cannabis dispensaries and cultivators. Navigating through state-by-state license, tax and compliance issues has been challenging for the legal cannabis industry. ezGreen Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations. For more information around a HIPAA compliance strategy for the Cannabis industry, please visit www.ezgreencompliance.com.

About FinCanna Capital Corp.
FinCanna is a royalty company that provides growth capital to rapidly emerging private companies operating in the licensed U.S cannabis industry.  The Company earns its revenue from royalties paid by its investee companies that are calculated based on a percentage of their total revenues.

FinCanna’s scalable royalty model provides an attractive alternative or complement to debt or equity financing for its investee companies. FinCanna is focused on delivering high-impact returns to its shareholders by way of a strategically diversified investment portfolio.

For additional information visit www.fincannacapital.com and www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Cautionary Note Regarding Forward-Looking Statements

Forward-Looking Information
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about the market for, and effectiveness of, ezGreen software, the ability of ezGreen Compliance to expand operations and generate sales and revenues, FinCanna’s ability to fund and source future projects, and FinCanna’s ability to earn and realize revenues from its investee companies.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement available at www.SEDAR.com and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

Click here to connect with FinCanna Capital Corp. (“FinCanna”) (CSE:CALI), (OTCQB:FNNZF) for an Investor Presentation. 

Source: www.globenewswire.com

Legal cannabis is spreading. According to a new report by Grand View Research, the global legal marijuana market is expected to reach US$73.6 billion by 2027 with a compound annual growth rate of 18.1 percent.

A survey of over 1,000 US consumers found that the modern cannabis user is largely representative of the general population. Moreover, cannabis consumption today blurs the lines between strictly recreational or medical. In fact, more than 50 percent of consumers report using cannabis for both purposes. As THC and CBD products make their way into an even wider array of product categories, our frame of reference for the modern cannabis user will continue to evolve.

In 2019, the medical cannabis market took home a leading revenue share of 71 percent, driven by the widespread adoption of cannabis as a pharmaceutical alternative for a wide range of conditions, including cancer, arthritis, Parkinson’s disease and more. A growing need for effective pain management therapies is expected to boost product demand even further.

This INNspired Article is brought to you by:

Khiron Life Sciences Corp. (TSXV:KHRN) is a vertically-integrated medical cannabis company fully licensed to conduct its core operations in Colombia.Send me an Investor Kit

Major telehealth platforms in the medical cannabis industry

Telehealth represents the intersection between innovative technology and the forefront of medical science. While remote medical practice saw its beginnings more than half a century ago, recent technological advancements have connected more patients to physicians than ever before.

In the US, platforms like NuggMD and IndicaMD provide patients with an online medical cannabis card that enables remote purchase of the drug. Patients can meet with physicians over secure video chat and can be approved to access cannabis within minutes. Physicians typically follow-up with patients by email, recommending the types of cannabis that would best alleviate their ailments and ensuring that they don’t purchase the wrong products. Other platforms exist to oversee the rapid delivery of cannabis and hemp products to patients across participating states.

Other parts of the world are undergoing the same transition. It has been more than eight years since Colombia — a country that represents more than a quarter of the world’s total export quotas — decriminalized the possession of small amounts of the drug, and roughly four years since the country legalized medical cannabis. In 2019, Colombia’s Constitutional Court overruled a ban on the public consumption of cannabis, which many considered a stepping stone toward full legalization. Recently, Colombia became one of the first countries in the world to extend national health insurance for patients requiring medical cannabis as a first-line therapy.

Khiron Life Sciences (TSXV:KHRN) was the first firm in Colombia authorized to sell both high and low THC formulations of medical cannabis. The company owns a telehealth platform that has accounted for over 5,600 medical cannabis prescriptions issued to date. Additionally, in June 2020 the company’s Doctor Zerenia telehealth platform was responsible for 14 percent of Khiron’s total medical consultations.

Since becoming the first company to fill medical cannabis prescriptions in Colombia, Khiron reports that 92 percent of its patients have experienced a marked improvement in their primary condition after four months of treatment. In light of these results, the Government of Colombia issued a directive that Khiron’s medical cannabis products and clinic services be covered by the country’s major health insurance providers. While countries such as Germany and the Czech Republic have taken similar legislative actions, a key difference in Colombia is that cannabis is considered a first line therapy with a vast array of applicable medical conditions. With more than 94 percent of Colombia’s population carrying health insurance policies, Colombia is quickly becoming one of the most favourable jurisdictions in the world for patient access; moreover, it has been shown that patient uptake is significantly increased by insurance coverage.

The next step forward for telehealth platforms includes opportunities such as virtual patient education and the fast, reliable delivery of essential drugs such as medical marijuana. Virtual care is also expected to expand across different types of patients, including those requiring intensive care. In the wake of the COVID-19 pandemic, many long-term care facilities have already adapted remote patient monitoring to maintain the safety of staff and patients.

The focus: Accessibility and improving patient outcomes

Medical marijuana has the power to improve patient outcomes across demographics. In the wake of groundbreaking research, patients, physicians and retailers are working together to increase the drug’s accessibility for patients who require relief from a range of health conditions. Telehealth platforms have been instrumental in not only increasing accessibility to medical marijuana, but also in improving quality of life across diverse populations of people.

A recent study completed by Canopy Growth (NASDAQ:CGC,TSX:WEED) in November 2020 found the absence of long-term toxicity despite long-term usage of CBD in a preclinical model, supporting the advancement of recent initiatives aimed at discovering CBD’s full range of therapeutic benefits. While CBD and tetrahydrocannabinol (THC) offer many of the same benefits, high levels of THC are responsible for most of cannabis’s psychoactive effects.

While the chronic pain segment dominated the medical cannabis market in 2019, application toward mental illness is expected to witness the fastest growth over the seven-year forecast period. Worldwide, a growing number of people suffer from depression, anxiety and other debilitating mental conditions with few low-risk pharmaceutical alternatives.

Medical cannabis is also becoming more popular among older adults. A recent study highlighted that cannabis use among individuals aged 65 and older has been steadily increasing, a trend that is consistent with reports from physicians who recommend cannabis in their daily practices. In the face of growing public acceptance and reduced stigma, we are beginning to see an increasing number of older adults rely on cannabis for relief against chronic pain, insomnia, neuropathy, anxiety and other conditions that traditionally call upon pharmaceuticals.

Much of the momentum in the medical cannabis market can be owed to the rise of telehealth platforms and health digitization efforts, increasing ease of access and promoting transparency. Over the next decade, legalization, increased awareness and the rise of remote medicine are expected to facilitate growth, creating lucrative opportunities for market stakeholders.

Takeaway

Telehealth platforms represent one of the easiest ways for patients, providers and retailers to collaborate remotely and fulfill needs faster. As more physicians and policymakers begin to recognize digital health tools as an advantage for maximizing efficiency and safety in health care, existing medical cannabis platforms are well-positioned to take advantage of a large-scale digital transition.

Keep reading... Show less

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less